Oxford Vacmedix Raises $12.5 Million for Therapeutic Vaccines from Asian Investors
Oxford Vacmedix, a UK-Changzhou biopharma, closed a $12.5 million Series A funding from South Korean and China investors to develop therapeutic cancer vaccines. OVM's two lead vaccines target cervical cancer and solid tumors, respectively, by stimulating CD4 and CD8 responses. The company expects the money will be enough to complete pre-clinical development of the vaccines and begin Phase I trials. Investors in the funding were Cancer ROP, a South Korea diagnostics company, and existing shareholders in China, who also supported the company's Changzhou facility. More details....
Share this with colleagues:
Original Article: Oxford Vacmedix Raises $12.5 Million for Therapeutic Vaccines from Asian Investors
NEXT ARTICLE
More From BioPortfolio on "Oxford Vacmedix Raises $12.5 Million for Therapeutic Vaccines from Asian Investors"
